A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cancer - Trial NCT06251388
Access comprehensive clinical trial information for NCT06251388 through Pure Global AI's free database. This Phase 2 trial is sponsored by West China Second University Hospital and is currently Recruiting. The study focuses on Cervical Cancer. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
West China Second University Hospital
Timeline & Enrollment
Phase 2
Feb 20, 2024
Oct 01, 2026
Primary Outcome
Progression-free survival
Summary
This study will evaluate the efficacy and safety of concurrent
 chemoradiotherapy（CCRT）followed by cadonilimab（AK104) in high risk local advanced cervical
 cancer.
 
 Participants received CCRT，efficacy evaluation of CCRT was no disease progression who
 maintained with AK104（10.0 mg/kg，Q3W）until drug exposure over 1 years or disease progression
 or intolerable toxicity.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06251388
Non-Device Trial